Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabhalta
Pharma
Novartis advances IgAN efforts with another phase 3 win
Novartis plans to leverage the trial data for regulatory submissions next year.
Eric Sagonowsky
Oct 16, 2025 9:30am
Novartis earns FDA ire for 'misleading' Fabhalta ad imagery
Sep 30, 2025 11:12am
Apellis snatches broad kidney disease expansion for Empaveli
Jul 28, 2025 8:00pm
Second Novartis drug in IgAN troika crosses FDA finish line
Apr 3, 2025 10:56am
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Mar 21, 2025 10:37am
CHMP again backs Leqembi amid flurry of approval recommendations
Feb 28, 2025 10:30am
